Trifarotene
Overview
Trifarotene is a selective retinoic acid receptor (RAR) gamma agonist that is used topically to treat acne vulgaris. It helps by promoting cell turnover, thereby reducing acne severity and maintaining skin health.
API suppliers (4)
Suppliers of Trifarotene evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
4 of 4 hold a GMP certificate on record in the EU or UK registers
- HAS Healthcare Advanced Synthesis SASwitzerland1 active DMF GMP on record
- OLON SPAItaly1 active DMF GMP on record
- Taro Pharmaceutical Industries Ltd.Israel1 active DMF GMP on record
- MAITHRI DRUGS PRIVATE LTDIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Trifarotene expires 30 May 2033. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Trifarotene? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.